Showing posts with label Cost. Show all posts
Showing posts with label Cost. Show all posts

Friday, September 27, 2013

0 Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy

Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy






Original Research


(250) Total Article Views





Authors: Ruggeri I, Bragato D, Colombo GL, Valla E, Di Matteo S


Published Date December 2012 Volume 2012:4 Pages 375 – 382
DOI: http://dx.doi.org/10.2147/CEOR.S36499
















Isabella Ruggeri,1 Donatello Bragato,2 Giorgio L Colombo,3,4 Emanuela Valla,3 Sergio Di Matteo4

1


Servizio Governo Area Farmaceutica, Azienda Sanitaria Locale, Milano, Binasco, 2Data Solution Provider, Milan, 3University of Pavia, Department of Drug Sciences, School of Pharmacy, 4Studi Analisi Valutazioni Economiche, Milan


Background: Bronchial asthma is a chronic airways disease and is considered to be one of the major health problems in the Western world. During the last decade, a significant increase in the use of β2-agonists in combination with inhaled corticosteroids has been observed. The aim of this study was to assess the appropriateness of expenditure on these agents in an asthmatic population treated in a real practice setting.
Methods: This study used data for a resident population of 635,906 citizens in the integrated patient database (Banca Dati Assistito) of a local health care unit (Milano 2 Azienda Sanitaria Locale) in the Lombardy region over 3 years (2007–2009). The sample included 3787–4808 patients selected from all citizens aged ≥ 18 years entitled to social security benefits, having a prescription for a corticosteroid + β2-agonist combination, and an ATC code corresponding to R03AK, divided into three groups, ie, pressurized (spray) drugs, inhaled powders, and extrafine formulations. Patients with chronic obstructive lung disease were excluded. Indicators of appropriateness were 1–3 packs per year (underdosed, inappropriate), 4–12 packs per year (presumably appropriate), and ≥13 packs per year (overtreatment, inappropriate).
Results: The corticosteroid + β2-agonist combination per treated asthmatic patient increased from 37% in 2007 to 45% in 2009 for the total of prescribed antiasthma drugs, and 28%–32% of patients used the drugs in an appropriate manner (4–12 packs per years). The cost of inappropriately used packs increased combination drug expenditure by about 40%, leading to inefficient use of health care resources. This trend improved during the 3-year observation period. The mean annual cost per patient was higher for powders (€223.95) and sprays (€224.83) than for extrafine formulation (€142.71).
Conclusion: Based on this analysis, we suggest implementation of better health care planning and more appropriate prescription practices aimed at optimizing use of health care resources for the treatment of bronchial asthma. The results of our study should be extended to other regional/national reference local health care units, in order to define and compare average standard costs per pathology, and consolidated through the wide sample considered.


Keywords: asthma, antiasthma drugs, general medicine, appropriateness, pharmacoeconomics, health economics



Tuesday, September 10, 2013

Saving Money on Volume: Obama Advisor Talks Cost Control With ASCO

Sometimes less is more. At least where healthcare reform and oncology are concerned, bringing volume down is the best path to reducing healthcare costs, according to Obama administration health advisor Ezekiel Emanuel.


Emanuel–an oncologist, a senior advisor in the Office of Management & Budget, and brother of White House Chief of Staff Rahm Emanuel–addressed a rapt audience at the American Society of Clinical Oncology annual meeting in Orlando, Fla. His May 30 presentation featured a polished presentation painting a vivid picture of escalating health care costs in a slide show reminiscent of Al Gore’s “An Inconvenient Truth.”


In this case, the inconvenient truth is not climate change, but the need to contain health care costs. “We cannot – in a responsible, sustainable way – get to universal coverage unless we’re going to take cost control seriously,” Emanuel said.


Emanuel boiled it all down to a simple equation: the combined pressures of price and volume combine for a constant increase in health care costs. That means continued, unsustainable growth unless there is a direct effect on price or volume.


Driving prices down would be great, he said. But for now, at least for Emanuel and for the medical practitioner audience at ASCO, the focus is volume – specifically, reducing unnecessary services. “I go where the money is,” he explained afterwards. Most of the increase in health spending comes from volume, not price, so that’s the appropriate target. “By and large affecting price will have … a relatively small effect” on overall cost trends.


“If you really want to hit the big time and bend the curve so it doesn’t go up exponentially, you’ve got to do volume,” Emanuel says. “There’s just no two ways about it.”


In oncology especially, the payment system tends to reward utilization rather than encourage evidence-based practice decisons. For instance, Emanuel argues, there should be a reduction in imaging and other screening practices since evidence doesn’t support a distinction in survival with high intensity follow-up.


For biopharma companies concerned about the prospects of price controls, Emanuel’s analysis suggests attention will be focused elsewhere. Drugs, though a high value target for public and media attention, just are not a big enough driver of cost to focus on when it comes to generating dramatic reductions in healthcare spending in the U.S. (Emanuel noted the widely accepted estimate that prescription drugs are only 10% of overall healthcare costs.)


That’s not to say there won’t be some push for realizing the gains that can be squeezed out of the pharmaceutical slice of the pie. The savings on price are relatively small “but they are not negligible,” he says, estimating that as much as 20%-25% of growth trends are affected by price.


Emanuel stressed generic utilization can make a difference. In cholesterol medicine, he says, 95 percent of patients can get as much benefit from the off-patent simvastatin as from the much more expensive Lipitor brand. Or, he suggested, generic albuterol versus branded asthma inhalers. “There you can make a difference in price.”


Then there is also the issue of utilization of high-priced therapies. Emanuel cited a favorite example–the low level of evidence to support use of Genentech’s Avastin – an argument he makes in his book Health Care Guaranteed. (See “The Avastin Dilemma: Two Personalities and Two Points of View on Cost Effectiveness,” The RPM Report, April 2009).


However, he added, if Avastin were a home run like the benefit from HER2-targeted breast cancer treatment (Genentech’s Herceptin), then it would be worth paying “almost anything.”


It’s a hard sell to think in terms of cost to society when there’s an individual patient looking for their best hope for life, and an especially hard sell in oncology where patient advocacy organizations push hard for access to experimental therapies. But Emanuel doesn’t shy away from hard truths, pointing out that all the innovation in oncology still hasn’t cured the disease.


Of the seven years that have been added to overall life expectancy since the 1960s, only two months can be attributed to new cancer treatments, Emanuel says. In contrast, he says, the impact from use of diuretics in hypertension can be measured in years.


For biopharma companies hoping to sell the next Avastin, the notion that health care reform advocates are touting the virtues of diuretics may be the most inconvenient truth of all.


-Mary Jo Laffler (m.laffler@elsevier.com)